How to Get Rezdiffra (Resmetirom) in Florida

Rezdiffra FDA Approval and Clinical Background

Resmetirom is the first FDA-approved medication specifically targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH. The FDA granted accelerated approval in March 2024 based on histological endpoints from the MAESTRO-NASH phase 3 trial 1.

MAESTRO-NASH Trial Results

In MAESTRO-NASH (N=966), resmetirom 80 mg and 100 mg achieved MASH resolution without worsening fibrosis in 25.9% and 29.9% of patients respectively at 52 weeks, compared with 9.7% for placebo 1. A fibrosis improvement endpoint (reduction by at least one stage with no worsening of NAFLD activity score) was met by 24.2% on the 80 mg dose and 25.9% on the 100 mg dose versus 14.2% on placebo 2.

Mechanism of Action

Resmetirom is a liver-directed thyroid hormone receptor beta (THR-beta) agonist. By selectively activating THR-beta in hepatocytes, it reduces hepatic fat, lowers atherogenic lipoproteins, and decreases inflammatory gene expression without systemic thyroid hormone effects 3. LDL-C reductions of 13% to 16% were observed as a secondary benefit in MAESTRO-NASH 1.

Who Qualifies for Rezdiffra in Florida

The FDA label restricts Rezdiffra to adults with MASH confirmed by biopsy or non-invasive testing plus evidence of moderate-to-advanced liver fibrosis (stages F2-F3) 2. Florida prescribers follow the same criteria.

Diagnostic Requirements

A FibroScan with a liver stiffness measurement (LSM) between 8.0 and 13.9 kPa generally corresponds to F2-F3 fibrosis 4. Alternatively, magnetic resonance elastography (MRE) or liver biopsy can confirm staging. The AASLD 2023 practice guidance recommends non-invasive testing as first-line fibrosis assessment in clinical practice 5.

Weight-Based Dosing

Patients weighing <100 kg receive the 80 mg tablet once daily. Those at or above 100 kg receive 100 mg once daily 2. Tablets are taken with food to optimize absorption.

Step-by-Step Prescription Process in Florida

Getting Rezdiffra filled in Florida involves a predictable sequence. Most patients complete the process within two to three weeks.

Step 1: Establish Care with a Qualified Provider

Florida law permits MDs, DOs, PAs, and APRNs (nurse practitioners) to prescribe Rezdiffra. Hepatologists and gastroenterologists have the most familiarity with MASH staging, but primary care physicians can prescribe if they document appropriate fibrosis staging. The Florida Board of Medicine does not restrict this drug to any single specialty 6.

Step 2: Obtain Required Baseline Labs

Before prescribing, your clinician will order:

• Comprehensive metabolic panel (CMP) with ALT, AST, and bilirubin
• TSH to rule out untreated thyroid disease (resmetirom is contraindicated in uncontrolled hypothyroidism)
• FibroScan or MRE for fibrosis staging
• Lipid panel (provides baseline for monitoring LDL reduction)
• Pregnancy test for women of childbearing potential

The FDA label requires periodic monitoring of hepatic function during treatment 2. The AASLD recommends repeat non-invasive fibrosis assessment at 12 months to evaluate treatment response 5.

Step 3: Prior Authorization Submission

Most commercial plans in Florida require prior authorization. Documentation typically includes:

• Confirmed MASH diagnosis (ICD-10 K75.81)
• Fibrosis stage F2 or F3 via FibroScan, MRE, or biopsy report
• BMI and metabolic comorbidity documentation
• Failure or contraindication to lifestyle modification (6+ months documented)
• Baseline LFT values

Turnaround time for PA decisions in Florida averages 5 to 14 business days per insurer reporting 7.

Step 4: Pharmacy Fill

Once approved, prescriptions route to a specialty pharmacy. CVS Specialty, Accredo, and AllianceRx Walgreens Prime carry Rezdiffra. Some Florida 503A compounding pharmacies licensed by the Florida Board of Pharmacy also dispense resmetirom under strict board oversight.

Telehealth Access in Florida

Florida statute 456.47 authorizes full prescriptive telehealth for Schedule VI (non-controlled) medications. Rezdiffra is not a controlled substance, so telehealth prescribing carries no additional regulatory barrier 8.

How Telehealth Visits Work for Rezdiffra

A telehealth hepatology or GI consultation typically lasts 20 to 30 minutes. You will need to upload or share FibroScan results, recent bloodwork, and imaging reports before the visit. The prescriber reviews staging documentation, confirms eligibility, and submits the prescription electronically.

Telehealth Limitations

Telehealth providers cannot perform a FibroScan remotely. You will still need an in-person FibroScan at a Florida imaging center or hospital outpatient department. LabCorp and Quest Diagnostics locations throughout Florida process the required bloodwork. Once staging is documented, subsequent follow-up visits can remain fully virtual 9.

Dr. Zobair Younossi, a leading MASH researcher and chair of the Global NASH Council, stated: "The approval of resmetirom represents a fundamental shift in how we can treat patients with NASH-related fibrosis. For the first time, we have a targeted pharmacotherapy that addresses the underlying hepatic pathology" 10.

Florida Medicaid and Insurance Coverage

Florida Medicaid does not currently list Rezdiffra on its preferred drug list for the MASH indication. Coverage through Florida Medicaid is limited to patients with concurrent type 2 diabetes where the drug may be considered off-formulary through exception 11.

Commercial Insurance in Florida

Major commercial payers operating in Florida (Florida Blue, Aetna, UnitedHealthcare, Cigna, Humana) have established medical policies for Rezdiffra. Most require step therapy documentation showing lifestyle intervention for at least 6 months prior to approval 12.

Cost Without Insurance

The wholesale acquisition cost (WAC) for Rezdiffra is approximately $47,400 per year. Madrigal Pharmaceuticals offers a copay assistance program reducing out-of-pocket costs to as low as $0 for eligible commercially insured patients, with a maximum annual benefit of $13,000 6.

503A Compounding Pharmacies in Florida

Florida's Board of Pharmacy licenses 503A compounding pharmacies under Chapter 465 of Florida Statutes. These pharmacies can compound medications for individual patients with a valid prescription.

Regulatory Framework

503A pharmacies in Florida must comply with USP <795> and USP <797> standards for non-sterile and sterile compounding respectively 13. Rezdiffra is an oral tablet, so non-sterile compounding standards apply. The pharmacy must source resmetirom API from an FDA-registered facility.

Shipping Within Florida

Florida-licensed 503A pharmacies can ship compounded resmetirom directly to patients within the state. Interstate shipping from out-of-state 503B outsourcing facilities is also legal under federal 503B regulations but requires the facility to register with the FDA 13.

Safety Monitoring and Follow-Up

The FDA label specifies monitoring requirements during Rezdiffra therapy that Florida providers must follow 2.

Liver Function Tests

Check ALT, AST, and bilirubin at baseline, monthly for the first 3 months, then every 3 months thereafter. Discontinue if ALT exceeds 5 times the upper limit of normal or if signs of hepatic decompensation develop.

Thyroid Monitoring

Despite liver selectivity, TSH should be checked at baseline and at 4 to 8 weeks. In MAESTRO-NASH, clinically significant thyroid abnormalities occurred in <1% of patients 1. Patients with pre-existing thyroid conditions on levothyroxine may need dose adjustment.

Gallbladder Events

Cholelithiasis occurred in 3.9% of resmetirom-treated patients versus 1.4% on placebo in the phase 3 trial 2. The Endocrine Society recommends awareness of gallbladder symptoms during THR-beta agonist therapy 14.

Transferring a Prescription to Florida

If you hold an active Rezdiffra prescription from another state, Florida pharmacies accept transferred prescriptions under Florida Administrative Code 64B16-27.410.

Transfer Process

Your current pharmacy contacts the receiving Florida pharmacy directly. The prescriber does not need to rewrite the prescription. Specialty pharmacies with multi-state licenses (CVS Specialty, Accredo) can internally transfer between their Florida and out-of-state locations within 24 to 48 hours 15.

New Patient Establishment

If you are establishing care with a new Florida provider, they may request updated labs and a new FibroScan before continuing the prescription. AASLD guidance supports repeat non-invasive assessment at treatment transitions 5.

Timeline: From First Visit to First Dose

The typical sequence in Florida:

1. Initial consultation (in-person or telehealth): Day 1
2. Labs and FibroScan completed: Days 1 to 7
3. Results reviewed, prescription written: Days 7 to 10
4. Prior authorization submitted and approved: Days 10 to 21
5. Specialty pharmacy ships medication: Days 21 to 24

Patients using Madrigal's bridge program may receive a 30-day supply while awaiting PA decisions, reducing the gap between prescription and first dose 6.

Drug Interactions Relevant to Florida Patients

Resmetirom has few clinically significant drug interactions. It is metabolized by CYP2C8 and CYP3A4 2.

Key Interactions

• Strong CYP2C8 inhibitors (gemfibrozil): Avoid concomitant use; increases resmetirom exposure
• Strong CYP3A4 inducers (rifampin, certain anticonvulsants): May reduce resmetirom efficacy
• Statins: No clinically meaningful interaction; can be co-administered 16

Given that MASH patients frequently take statins, metformin, and GLP-1 receptor agonists, the lack of interaction with these drug classes simplifies management 17.

Long-Term Outlook and Confirmatory Trial

Rezdiffra received accelerated approval, meaning continued marketing depends on confirmatory outcomes data. The MAESTRO-OUTCOMES trial (NCT05761406) is evaluating liver-related clinical events over 54 months 18. If this trial confirms benefit, full approval and broader insurer coverage in Florida are expected. Patients currently on therapy should continue as prescribed unless their provider advises otherwise based on new safety signals.